Rivaroxaban Monotherapy vs Combination Therapy With Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation With Stable Coronary Artery Disease: A Post Hoc Secondary Analysis of the AFIRE Trial.
- DOI
- 10.1001/jamacardio.2022.1561
- Published
- 2022 Aug 1
- Container
- JAMA cardiology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1001/jamacardio.2022.1561,
title = {Rivaroxaban Monotherapy vs Combination Therapy With Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation With Stable Coronary Artery Disease: A Post Hoc Secondary Analysis of the AFIRE Trial.},
author = {Naito R and Miyauchi K and Yasuda S and Kaikita K and Akao M and Ako J and Matoba T and Nakamura M and Hagiwara N and Kimura K and Hirayama A and Matsui K and Ogawa H and AFIRE Investigators},
year = {2022},
journal = {JAMA cardiology},
doi = {10.1001/jamacardio.2022.1561},
url = {https://doi.org/10.1001/jamacardio.2022.1561}
}RIS
TY - JOUR TI - Rivaroxaban Monotherapy vs Combination Therapy With Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation With Stable Coronary Artery Disease: A Post Hoc Secondary Analysis of the AFIRE Trial. AU - Naito R AU - Miyauchi K AU - Yasuda S AU - Kaikita K AU - Akao M AU - Ako J AU - Matoba T AU - Nakamura M AU - Hagiwara N AU - Kimura K AU - Hirayama A AU - Matsui K AU - Ogawa H AU - AFIRE Investigators PY - 2022 JO - JAMA cardiology DO - 10.1001/jamacardio.2022.1561 UR - https://doi.org/10.1001/jamacardio.2022.1561 ER -
APA
R, N., K, M., S, Y., K, K., M, A., J, A., T, M., M, N., N, H., K, K., A, H., K, M., H, O., & Investigators, A. (2022). Rivaroxaban Monotherapy vs Combination Therapy With Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation With Stable Coronary Artery Disease: A Post Hoc Secondary Analysis of the AFIRE Trial.. JAMA cardiology. https://doi.org/10.1001/jamacardio.2022.1561
Source records
- pubmed · retrieved 2026-09-26T03:02:08.642Z